ライフサイエンスコーパス: serum potassium

1 0.83; 95% CI: 0.74, 0.92 per SD increment in serum potassium).

2 th sympatho-adrenal activation and a lowered serum potassium.

3 hat occurs in association with a decrease in serum potassium.

4 be nearly normalized by modest elevation of serum potassium.

5 a lower risk of diabetes than was low-normal serum potassium.

6 rs, use of antihypertensive medications, and serum potassium.

7 understand how acid-base disturbances affect serum potassium.

8 and contractile failure correlated with low serum potassium.

9 um (0.44+/-0.14 mmol/L, P=0.02), and lowered serum potassium (0.11+/-0.02 mmol/L, P<0.0001).

10 was common (52/104 [50%]), as were abnormal serum potassium (32/97 [33%]), severe hepatitis (54/92 [

11 normal axonal resting potentials had normal serum potassium, although urea and creatinine were eleva

12 y but significant and persistent (1) rise in serum potassium and (2) reduction in estimated glomerula

13 , we found a significant interaction between serum potassium and aldosterone (P = 0.046).

14 s index, net endogenous acid production, and serum potassium and bicarbonate), hazard ratios of the c

15 it from candesartan, careful surveillance of serum potassium and creatinine is particularly important

16 mg once daily with recommended monitoring of serum potassium and creatinine.

17 The changes in serum potassium and estimated glomerular filtration rate

18 Hypothermic rats had lower serum potassium and higher blood glucose concentrations

19 ne concentrations were associated with lower serum potassium and higher urinary excretion of potassiu

20 we found no significant association between serum potassium and incident diabetes.

21 dosterone may modify the association between serum potassium and incident diabetes.

22 Aldosterone affects serum potassium and is associated with insulin resistanc

23 nal incidentaloma; additional measurement of serum potassium and plasma aldosterone concentration-pla

24 en aldosterone and MR activity, assessed via serum potassium and urinary fractional excretion of pota

25 e guidelines recommend routine monitoring of serum potassium, and renal function in patients treated

26 Racial differences in serum potassium appeared to explain 18% of the excess ri

27 Low serum potassium appears to be independently associated w

28 The serum potassium AUC increased with the dose (P < 0.0001)

29 62.5% of patients; severe hyperkalemia (peak serum potassium concentration > or = 5.5 mmol/L) occurre

30 ARBs) may increase the risk of hyperkalemia (serum potassium concentration >5 mmol/L) in the setting

31 The steady-state serum potassium concentration frequently changes during

32 A peak serum potassium concentration greater than 5.0 mmol/L de

33 cathartic, but the effect of such therapy on serum potassium concentration has not been established.

34 he effect of increasing dietary potassium on serum potassium concentration in hypertensive individual

35 The serum potassium concentration in the control group was 4

36 The serum potassium concentration in the treatment group (me

37 Serum potassium concentration increased from 3.0 mmol/L

38 On placebo therapy, the average serum potassium concentration increased slightly (0.4 mE

39 Fecal potassium output and serum potassium concentration were measured for 12 h.

40 Serum potassium concentration, 3-d food records, and 24-

41 py produces no or only trivial reductions in serum potassium concentration, and because this therapy

42 lator therapy was independent of the initial serum potassium concentration.

43 a variety of medications that can alter the serum potassium concentration.

44 ith structural heart disease and an abnormal serum potassium concentration.

45 le option for controlling blood pressure and serum potassium concentration.

46 t various infections leads to an increase in serum potassium concentration.

47 gimens were associated with a slight rise in serum potassium concentrations (similar to placebo); thi

48 he treatment and control groups had the same serum potassium concentrations and did not receive diffe

49 Mean serum potassium concentrations decreased from 4.9 mmol/L

50 increased potassium intake in the HKD group, serum potassium concentrations did not significantly inc

51 Low serum potassium concentrations in African Americans may

52 Whether interventions to increase serum potassium concentrations in African Americans migh

53 (95% CI) of incident diabetes for those with serum potassium concentrations of <4.0, 4.0-4.4, and 4.5

54 of the study, when clinically indicated, for serum potassium concentrations of 3.5 mmol/L or serum ma

55 and 4.5-4.9 mEq/L, compared with those with serum potassium concentrations of 5.0-5.5 mEq/L (referen

56 Mean serum potassium concentrations were lower in African Ame

57 lectrolyte abnormalities, including abnormal serum potassium concentrations, are considered a correct

58 None of the regimens reduced serum potassium concentrations, compared with baseline l

59 ed hypertension are now known to have normal serum potassium concentrations.

60 We hypothesized that low serum potassium contributes to the excess risk of diabet

61 An increase in serum potassium corrects abnormalities of repolarization

62 The increases in serum potassium did not translate into increased cardiac

63 Hs) of incident diabetes related to baseline serum potassium during 9 y of follow-up.

64 he 285 patients who received spironolactone, serum potassium exceeded 6.0 mmol/L on one occasion.

65 losilicate in outpatients with hyperkalemia (serum potassium >/=5.1 mEq/L) recruited from 44 sites in

66 ient-reported hypoglycemia and hyperkalemia (serum potassium>5.5 mEq/L), respectively.

67 ological ionic strength, and (3) response to serum potassium in the presence of fouling biological co

68 xercise, and atrial pacing, before and after serum potassium increase.

69 ho received placebo, urine potassium but not serum potassium increased significantly among participan

70 l studies are warranted to determine whether serum potassium is a modifiable risk factor that could b

71 ing of blood pressure, serum creatinine, and serum potassium is warranted.

72 xamined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Epl

73 Guidelines recommend measurement of serum potassium (K) and creatinine (Cr) before and seria

74 ronounced in patients with lower predialysis serum potassium (K) levels (HR 2.53 [P = 0.01] for K <4.

75 asting hours to days associated with reduced serum potassium (K+).

76 iltration rate, 15 to <60 mL/min/1.73 m2 and serum potassium level >5.0 mEq/L).

77 s and were categorized by mean postadmission serum potassium level (<3.0, 3.0-<3.5, 3.5-<4.0, 4.0-<4.

78 tiromer was titrated to achieve and maintain serum potassium level 5.0 mEq/L or lower.

79 ed in statistically significant decreases in serum potassium level after 4 weeks of treatment, lastin

80 aped relationship between mean postadmission serum potassium level and in-hospital mortality that per

81 he association between abnormal preoperative serum potassium level and perioperative adverse events s

82 lamines, and, in the hypertensive patient, a serum potassium level and plasma aldosterone concentrati

83 s the exponential rate of change in the mean serum potassium level at 48 hours.

84 east squares mean reduction from baseline in serum potassium level at week 4 or time of first dose ti

85 d the need for CPR increased as preoperative serum potassium level decreased below 3.5 mmol/L.

86 rimary efficacy end point was mean change in serum potassium level from baseline to week 4 or prior t

87 fficacy end point was the mean change in the serum potassium level from baseline to week 4.

88 At 48 hours, the mean serum potassium level had decreased from 5.3 mmol per li

89 The primary end point was mean serum potassium level in each zirconium cyclosilicate gr

90 Patients were stratified by baseline serum potassium level into mild or moderate hyperkalemia

91 sociation between increased need for CPR and serum potassium level less than 3.3 mmol/L (OR, 3.3; 95%

92 Serum potassium level less than 3.5 mmol/L was a predict

93 group difference in the median change in the serum potassium level over the first 4 weeks of that pha

94 efficacy end points included mean change in serum potassium level through 52 weeks.

95 after day 3, the mean (+/-SE) change in the serum potassium level was -1.01+/-0.03 mmol per liter (P

96 Her serum potassium level was 13.1 mEq/L and HCO3- was 16 mE

97 Serum potassium level was measured at every study visit.

98 Serum potassium level was significantly higher with the

99 Hypokalemia (low serum potassium level) is a common electrolyte imbalance

100 he proportion of patients with hyperkalemia (serum potassium level, >/=6 mmol per liter) was signific

101 Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associate

102 Patients with normokalemia (serum potassium level, 3.5 to 4.9 mmol per liter) at 48

103 CT images, aldosterone-to-renin ratio (ARR), serum potassium level, and blood pressure control were a

104 Spironolactone also modestly increased serum potassium levels (+0.2 mmol/L; 95% CI, +0.1 to +0.

105 demonstrated smaller percentage increases in serum potassium levels (as determined by %AUC; 4.3+/-6.8

106 Safety was established through serial serum potassium levels and measurement of cystatin C, a

107 treatment was associated with a decrease in serum potassium levels and, as compared with placebo, a

108 ity was observed in those with postadmission serum potassium levels between 3.5 and <4.5 mEq/L compar

109 al practice guidelines recommend maintaining serum potassium levels between 4.0 and 5.0 mEq/L in pati

110 In the open-label phase, serum potassium levels declined from 5.6 mEq/L at baseli

111 ither modeled continuously or categorically, serum potassium levels during long-term monitoring were

112 ovel selective cation exchanger, could lower serum potassium levels in patients with hyperkalemia.

113 Mean serum potassium levels increased from 2.6 mmol/L +/- 0.4

114 o were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to less than 6.5 mmol per

115 yclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have spa

116 Serum potassium levels rise substantially during vigorou

117 of ZS-9 and those who received 10 g of ZS-9, serum potassium levels were maintained at 4.7 mmol per l

118 statistically significant mean decreases in serum potassium levels were observed at each monthly poi

119 the hemodialysis prescription is to maintain serum potassium levels within a narrow normal range duri

120 itable, and which may be precipitated by low serum potassium levels.

121 tration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.

122 All patients had in-hospital serum potassium measurements and were categorized by mea

123 There were 13 abnormal serum potassium measurements in 1802 measurements obtain

124 hange in practice will require more frequent serum potassium monitoring and responsive dialysis care

125 s, as well as with interventions to increase serum potassium more than was achieved with our interven

126 ryngeal temperature of 13.8 degrees C, and a serum potassium of 11.3 mmol/L.

127 laboratory values, and 34% did not have any serum potassium or creatinine determined within three mo

128 icant changes in heart rate, blood pressure, serum potassium, or renal function were observed.

129 over the study period for serum bicarbonate, serum potassium, or urine chloride end points.

130 he former, superexcitability correlated with serum potassium (R = 0.88), and late subexcitability was

131 ity parameters correlated significantly with serum potassium (range 4.3-6.1 mM), but not with other m

132 ssible in children with body temperature and serum potassium reaching the far limits of previously re

133 articularly increased blood pressure and low serum potassium) related to the stimulation of aldostero

134 ihypertensive medication, diabetes mellitus, serum potassium, serum albumin, high-density lipoprotein

135 , KCl at a dose of 40 mEq/d did not increase serum potassium significantly.

136 oncentrations supports the practice of using serum potassium to guide potassium replacement in patien

137 label sodium zirconium cyclosilicate reduced serum potassium to normal levels within 48 hours; compar

138 y and had lower levels of plasma glucose and serum potassium upon oral glucose stimulation and increa

139 e was prescribed to 22.8% of patients with a serum potassium value > or =5.0 mmol/L, to 14.1% with a

140 (RR, 2.75; 95% CI, 2.14-3.52) or an abnormal serum potassium value if they were aged >/=76 years (RR,

141 sought to determine the association between serum potassium values collected at follow-up with all-c

142 Despite the same serum potassium values, the net potassium balance for 48

143 In a minimally adjusted model, serum potassium was a significant predictor of incident

144 cipants with normal aldosterone, high-normal serum potassium was associated with a lower risk of diab

145 Serum potassium was measured at every physician-patient

146 In the randomized phase, serum potassium was significantly lower during days 8-29

147 estimated glomerular filtration rate and in serum potassium were available in 2737 patients during a

148 of nonsustained ventricular tachycardia, and serum potassium were related to sudden cardiac death.

149 The multivariable-adjusted association of serum potassium with mortality was assessed by using com

150 -concordant testing for serum creatinine and serum potassium within 180 days before or 14 days after

151 We hypothesized that an increase in serum potassium would normalize repolarization in these